These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

82 related articles for article (PubMed ID: 17244174)

  • 1. Remission of severely impaired subjective wellbeing in 727 patients with schizophrenia treated with amisulpride.
    Lambert M; Naber D; Eich FX; Schacht M; Linden M; Schimmelmann BG
    Acta Psychiatr Scand; 2007 Feb; 115(2):106-13. PubMed ID: 17244174
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Early- and delayed antipsychotic response and prediction of outcome in 528 severely impaired patients with schizophrenia treated with amisulpride.
    Lambert M; Schimmelmann BG; Naber D; Eich FX; Schulz H; Huber CG; Karow A
    Pharmacopsychiatry; 2009 Nov; 42(6):277-83. PubMed ID: 19924588
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Achieving symptomatic remission in out-patients with schizophrenia--a naturalistic study with quetiapine.
    Wobrock T; Köhler J; Klein P; Falkai P
    Acta Psychiatr Scand; 2009 Aug; 120(2):120-8. PubMed ID: 19392812
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Quality of life and subjective well-being in schizophrenia and schizophrenia spectrum disorders: valid predictors of symptomatic response and remission?
    Schennach-Wolff R; Jäger M; Obermeier M; Schmauss M; Laux G; Pfeiffer H; Naber D; Schmidt LG; Gaebel W; Klosterkötter J; Heuser I; Kühn KU; Lemke MR; Rüther E; Klingberg S; Gastpar M; Seemüller F; Möller HJ; Riedel M
    World J Biol Psychiatry; 2010 Aug; 11(5):729-38. PubMed ID: 20380620
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Quality of life and subjective well-being during treatment with antipsychotics in out-patients with schizophrenia.
    Wehmeier PM; Kluge M; Schneider E; Schacht A; Wagner T; Schreiber W
    Prog Neuropsychopharmacol Biol Psychiatry; 2007 Apr; 31(3):703-12. PubMed ID: 17289237
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Amisulpride versus risperidone in the treatment of depression in patients with schizophrenia: a randomized, open-label, controlled trial.
    Kim SW; Shin IS; Kim JM; Lee SH; Lee JH; Yoon BH; Yang SJ; Hwang MY; Yoon JS
    Prog Neuropsychopharmacol Biol Psychiatry; 2007 Oct; 31(7):1504-9. PubMed ID: 17692448
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Improvement of subjective well-being and enduring symptomatic remission, a 5-year follow-up of first episode schizophrenia.
    de Haan L; Nimwegen Lv; Amelsvoort Tv; Dingemans P; Linszen D
    Pharmacopsychiatry; 2008 Jul; 41(4):125-8. PubMed ID: 18651339
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Patterns of physician and patient rated quality of life during antipsychotic treatment in outpatients with schizophrenia.
    Wehmeier PM; Kluge M; Schacht A; Helsberg K; Schreiber W; Schimmelmann BG; Lambert M
    J Psychiatr Res; 2008 Jul; 42(8):676-83. PubMed ID: 17720192
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Remission in schizophrenia: analysis in a naturalistic setting.
    Eberhard J; Levander S; Lindström E
    Compr Psychiatry; 2009; 50(3):200-8. PubMed ID: 19374962
    [TBL] [Abstract][Full Text] [Related]  

  • 10. THE LESSA (Lebanese Short-term Study with Amisulpride) STUDY a Phase IV clinical trial in acutely ill schizophrenic patients.
    Baddoura R; Ourgandjian H
    J Med Liban; 2004; 52(2):78-85. PubMed ID: 15884686
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Improvement of patient compliance after switching from conventional neuroleptics to the atypical neuroleptic amisulpride.
    Linden M; Scheel T; Eich FX
    J Psychopharmacol; 2006 Nov; 20(6):815-23. PubMed ID: 16401647
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lower subjective quality of life and the development of social anxiety symptoms after the discharge of elderly patients with remitted schizophrenia: a 5-year longitudinal study.
    Kumazaki H; Kobayashi H; Niimura H; Kobayashi Y; Ito S; Nemoto T; Sakuma K; Kashima H; Mizuno M
    Compr Psychiatry; 2012 Oct; 53(7):946-51. PubMed ID: 22554765
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Predictors of subjective and objective quality of life in outpatients with schizophrenia.
    Yamauchi K; Aki H; Tomotake M; Iga J; Numata S; Motoki I; Izaki Y; Tayoshi S; Kinouchi S; Sumitani S; Tayoshi S; Takikawa Y; Kaneda Y; Taniguchi T; Ishimoto Y; Ueno S; Ohmori T
    Psychiatry Clin Neurosci; 2008 Aug; 62(4):404-11. PubMed ID: 18778437
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment response in psychotic patients classified according to social and clinical needs, drug side effects, and previous treatment; a method to identify functional remission.
    Alenius M; Hammarlund-Udenaes M; Hartvig P; Sundquist S; Lindström L
    Compr Psychiatry; 2009; 50(5):453-62. PubMed ID: 19683616
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparative remission rates of schizophrenic patients using various remission criteria.
    Beitinger R; Lin J; Kissling W; Leucht S
    Prog Neuropsychopharmacol Biol Psychiatry; 2008 Oct; 32(7):1643-51. PubMed ID: 18616969
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Amisulpride augmentation in patients with schizophrenia partially responsive or unresponsive to clozapine. A randomized, double-blind, placebo-controlled trial.
    Assion HJ; Reinbold H; Lemanski S; Basilowski M; Juckel G
    Pharmacopsychiatry; 2008 Jan; 41(1):24-8. PubMed ID: 18203048
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Subjective assessments of the quality of life, well-being and self-efficacy in patients with schizophrenia.
    Chino B; Nemoto T; Fujii C; Mizuno M
    Psychiatry Clin Neurosci; 2009 Aug; 63(4):521-8. PubMed ID: 19531107
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Remission in schizophrenia: one-year Italian prospective study of risperidone long-acting injectable (RLAI) in patients with schizophrenia or schizoaffective disorder.
    Rossi A; Bagalà A; Del Curatolo V; Scapati F; Bernareggi MM; Giustra MG;
    Hum Psychopharmacol; 2009 Oct; 24(7):574-83. PubMed ID: 19790173
    [TBL] [Abstract][Full Text] [Related]  

  • 19. One-year outcome and its prediction in first-episode schizophrenia--a naturalistic study.
    Bachmann S; Bottmer C; Schroder J
    Psychopathology; 2008; 41(2):115-23. PubMed ID: 18059113
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Oral versus injectable antipsychotic treatment in early psychosis: post hoc comparison of two studies.
    Emsley R; Oosthuizen P; Koen L; Niehaus DJ; Medori R; Rabinowitz J
    Clin Ther; 2008 Dec; 30(12):2378-86. PubMed ID: 19167596
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.